Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.

Published in:

Rheumatology & Therapy, 2019, v. 6, n. 4, p. 503, doi. 10.1007/s40744-019-00167-6

By:

• Genovese, Mark C.;
• Greenwald, Maria W.;
• Gutierrez-Ureña, Sergio R.;
• Cardiel, Mario H.;
• Poiley, Jeffrey E.;
• Zubrzycka-Sienkiewicz, Anna;
• Codding, Christine E.;
• Wang, Annie;
• He, Weizhong;
• Amos, Rebecca;
• Vinueza, Raul;
• Wang, Xuegong;
• Garg, Jay P.;
• Kivitz, Alan J.

Publication type:

Article